Yuri - Space Biotech for a Better Life!
June 16, 2025
Company Presentation
Tools/Drug Development Support Tech
Yuri is a leading commercial space biotech company that leverages the unique conditions of microgravity to research and develop groundbreaking biotechnological innovations and providing the implementation services (Yuri Lab-as-a-Service). With over 25 successful research missions to the ISS and partnerships with NASA, ESA, GSK, Charité Berlin, and MIT, our interdisciplinary team of aerospace engineers and biologists is taking pharmaceutical and biotech research to a new level—advancing drug discovery, optimized biomaterials, and sustainable food production processes both in space and on Earth. To achieve these goals Yuri manufactures space-based multi-user research, production and fabrication facilities for commercial biotechnology and pharma companies as well as international space agencies. Together with its partners, Yuri builds up the future commercial in-space life-science infrastructure.
Company HQ City:
Meckenbeuren
Company HQ State:
Baden-Wuerttemberg
Company HQ Country:
Germany
Year Founded:
2019
Lead Product in Development:
There are three lead products we are working on! 1. Is the Yuri Science- or Lab-as-a-Service therefore we over the implementation of research, production and fabrication in microgravity for our customers. 2. We found a gen against TNBC, we are working on the patent and want to find a partner. 3. Yuri Retina Organoid - Retina Organoid which we have grown within simulated microgravity and the results are insane, we are working on the patent right now.
CEO
Maria Birlem, Co-Founder & CEO
Christian Bruderrek, Co-Founder & COO
Development Phase of Lead Product
Discovery
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
We are currently launching a pilot project with a multinational pharmaceutical company to explore organoid research in microgravity. This initiative aims to leverage space-based conditions for advanced drug discovery and disease modeling, paving the way for new biotechnological applications in regenerative medicine and precision therapies.
What is your next catalyst (value inflection) update?
We expect the update within Q3/Q4 of 2025 right before we are moving into our Series A round.
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}